Investor Presentaiton
HANLIKANG (Rituximab): Strengthen the Market Leader Position
541M RMB
Revenue recognized by Henlius and
licensing income in 2023
Total revenue recognized by Fosun Pharma
•
•
.
•
Acceleration on market access
and penetration
Approved in February 2019 as the first
approved biosimilar in China, the first
approved rituximab biosimilar in China
New indication approved in February
2022: the first rituximab approved for
Rheumatoid Arthritis indication in China
Solid market leader position
Market leader for rituximab in China with
speedy share growth since launch
Gained the largest market share for
consecutive quarters, 49% in Q3 2023*
Commercialization Progress
Jiangsu Fosun, a subsidiary of Fosun
Pharma, is responsible for HANLIKANG'S
commercialization in China
Listed on the procurement platforms and
covered by NRDL in all provinces in China
-6%
575
541
2022
2023
In Million
RMB
FOSUN PHARMA
Henlius
Henlius FOSUN PHARMA
*
利妥昔单抗注射液
利妥昔单抗注射液
汉利康 ®
500mg/50ml
150m
|利妥昔单抗注射液
稀释后缓慢静脉输注
50mg/50ml
|释后缓慢静脉输注
往上许可许有人;上海望宏汉群生照料需有财
生产企业:上海复密汉程生物院病有限公司
15
* Source: Henlius internal analysis
汉利康。
100mg/10ml
糀释卮燥悛静脉输注
利妥昔单抗注鍋
ANA
Drug Specifications:
100mg/10ml/bottle
500mg/50ml/bottle
Ⓒ Target: CD20 Indications:
Non-Hodgkin lymphoma
Chronic lymphocytic leukemia
Rheumatoid Arthritis (RA)
2024 Henlius.
2 HenliusView entire presentation